Teva resolutely decided to leverage its outstanding scientific resources, global leadership and scale to develop new innovative products that will make a real difference in people's lives.
On average, 5,000 to 10,000 compounds need to be screened in order to discover a new organic molecule, peptide or protein that can be used to treat or cure a disease. It can take 10-15 years to develop an innovative drug and costs can rise to over $1 billion.
Regulators demand that innovative products show distinct advantages to already existing products. Consequently, costs of development consistently rise and development time continuously increases.
An innovative drug is the result of a discovery of a new organic substance and the research of how it can be used to treat or cure diseases
More »
CMC assures that each element in a clinical trial is pre-checked and assessed in order to prevent the risk of using a flawed compound
Pre-clinical trials assess the compound’s safety, ADME and PK
Clinical trials are conducted in three main phases; each addresses different questions and determines whether the testing can proceed to the
The regulatory authority reviews the regulatory package and reaches a final decision. Upon approval, marketing activities commence
Production commences in compliance with Good Manufacturing Practice (GMP) regulations, and once completed, a new innovative drug is launched
Teva conducts ongoing surveillance of innovative drugs' safety, adverse reactions and side effects to protect public health
Teva is the leading generic pharmaceutical company in the world and has one of the broadest product pipeline in the industry.
With: 56 pharmaceutical production plants; 34 generic and innovate R&D sites; 21 API production facilities; Approximately 180 product applications awaiting final FDA approval; Approximately 75 first to file applications pending in the US; 1,846 generic approvals in Europe, as of December 2010; Over 2,500 marketing authorization applications pending approval in 30 European countries.
Teva aspires to be the first to market high quality, affordable, generic medicines. How do we do it?
Many factors are taken into account when considering whether to develop a generic drug
Teva has the largest generic R&D team in the pharmaceutical industry
A generic drug should be therapeutically equivalent to its reference innovative drug. To ensure therapeutic equivalence, bioequivalence studies are conducted
Obtaining a Marketing Authorization from the regulators confirms that the generic drug is of high quality, safe and effective
Teva's vast supply chain meets the most challenging deadlines, delivering high quality generic products by land, sea or air